Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Imperial College London
Age
21–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy non-smokers: normal spirometry (forced expiratory volume in 1 second \[FEV1\] more than or equal to 90% predicted) and normal exhaled NO (between 8 and 24 ppb; flow 50 ml/s)
0: At risk (current or ex-smokers): normal spirometry, with or without chronic symptoms (cough, sputum production)
I-II: Mild-moderate COPD
* FEV1 reversibility of \< 15% after inhaled beta2-agonists
* FEV1 between greater than or equal to 50% and less than 80%
* With or without chronic symptoms (cough, sputum production)
Able to comprehend and grant a written informed consent
You may not be if
Concomitant use or pre-treatment within the last 4 weeks with oral steroids
Respiratory infection within 4 weeks prior to entry into the trial
Females who are pregnant or lactating
History of current or past drug or alcohol abuse
Clareo Health | Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)
